Tomohiko Ishibashi

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Oral Pathobiont Streptococcus Anginosus Is Enriched in the Gut of Stroke Patients and Predicts 2-Year Cardiovascular Outcome.

Oral Pathobiont Streptococcus Anginosus Is Enriched in the Gut of Stroke Patients and Predicts 2-Year Cardiovascular Outcome.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: June 04, 2025

Balloon Pulmonary Angioplasty in Heterozygous RNF213 p.Arg4810Lys Variant Carriers Diagnosed With Chronic Thromboembolic Pulmonary Hypertension.

Balloon Pulmonary Angioplasty in Heterozygous RNF213 p.Arg4810Lys Variant Carriers Diagnosed With Chronic Thromboembolic Pulmonary Hypertension.

Journal: Journal of the American Heart Association

Published: April 16, 2025

A Novel Missense Variant of ZC3H12A in Pulmonary Arterial Hypertension.

A Novel Missense Variant of ZC3H12A in Pulmonary Arterial Hypertension.

Journal: Circulation reports

Published: January 15, 2025

Medial Dissection Following Balloon Angioplasty in Peripheral Pulmonary Artery Stenosis Harbouring Homozygous RNF213 p.Arg4810Lys Variant.

Medial Dissection Following Balloon Angioplasty in Peripheral Pulmonary Artery Stenosis Harbouring Homozygous RNF213 p.Arg4810Lys Variant.

Journal: CJC open

Published: October 17, 2024

Gut Dysbiosis in Patients With Fontan Circulation.

Gut Dysbiosis in Patients With Fontan Circulation.

Journal: Journal of the American Heart Association

Published: September 09, 2024

Prevalence and Clinical Characteristics of Heterozygous RNF213 p.Arg4810Lys Variant Carriers Diagnosed With Chronic Thromboembolic Pulmonary Hypertension.

Prevalence and Clinical Characteristics of Heterozygous RNF213 p.Arg4810Lys Variant Carriers Diagnosed With Chronic Thromboembolic Pulmonary Hypertension.

Journal: Journal of the American Heart Association

Published: July 26, 2024

IL-6/gp130 signaling in CD4+ T cells drives the pathogenesis of pulmonary hypertension.

IL-6/gp130 signaling in CD4+ T cells drives the pathogenesis of pulmonary hypertension.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 11, 2024

Current Immunosuppressive Treatment for Takayasu Arteritis.

Current Immunosuppressive Treatment for Takayasu Arteritis.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: December 20, 2023

Gut dysbiosis is associated with aortic aneurysm formation and progression in Takayasu arteritis.

Gut dysbiosis is associated with aortic aneurysm formation and progression in Takayasu arteritis.

Journal: Arthritis research & therapy

Published: November 12, 2022

Biomarkers for Takayasu arteritis: Which is the most promising?

Biomarkers for Takayasu arteritis: Which is the most promising?

Journal: International journal of cardiology

Published: September 09, 2022

Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.

Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.

Journal: Circulation

Published: August 23, 2022

Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension.

Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 10, 2021

Showing 1-12 of 25

Last Updated: 09/26/2026